View Clinical Trial (Medical Research Study)

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine - NCT00775463-15261(Clinical Trial 248320)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Pittsburgh
State:  
PA
Zip Code: 15261
Conditions: Systemic Sclerosis - Scleroderma
Purpose: This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.
Study summary:
Criteria: Inclusion Criteria: - Subject gives voluntary written informed consent to participate in the study. - Diagnosis of systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria. - Males and females age greater than 18 years - Presence of at least one active digital ulcer (meets protocol defined qualifications for active digital ulcer) - Females of childbearing potential must be willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test - Able to communicate effectively with study personnel and willing to comply with protocol requirements. Exclusion Criteria: - Diagnosis of pulmonary arterial hypertension (PAH). - Body weight less than 40 kg - History of postural hypotension, unexplained syncope, a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening and Baseline. - Hemoglobin concentration less than 75% of the lower limit of the normal range - Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C. - Intractable diarrhea, or severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening; any severe organ failure (e.g., lung, kidney), bleeding diathesis or platelet disorder, or any life-threatening condition. - Pregnancy or breast-feeding. - Overlap with another connective tissue disease that could affect rest pain and hand function (e.g. diabetes mellitus, rheumatoid arthritis). - Sympathectomy of the upper limb performed within 12 months of Baseline. Sympathectomy performed on the non-target limb (hands not presenting with qualifying ulcers) or which did not include the hand performed within 6 months of Baseline. - Receipt of prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months of Baseline for conditions including Reynaud's phenomenon, rest pain and / or digital ulcers. - Required systemic antibiotics for infected digital ulcers within 2 weeks of Screening. - Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline. - Treatment with endothelin receptor antagonists within 1 month prior to Baseline. - Patients on phosphodiasterase inhibitors, such as sildenafil, or tadalafil, who have received treatment for less than 6 months prior to Baseline (unless for intermittent treatment of male erectile dysfunction). - Treatment with statin within 1 month prior to Screening, unless for management of hyperlipidemia. - Received an investigational product within 1 month preceding Screening. - Known hypersensitivity to treprostinil diethanolamine or any of the excipients. - Tobacco use at any level within the past 6 months prior to Screening.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: January 5, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.